Greetings! We are exploring apoptosis induced in B cell lines by antineoplastic drugs. We suspect that induction of FAS ligand may play a role with one or more drugs. Antibodies to FAS-L exist and an Fc fragment that inhibits binding of FAS-L to the FAS receptor is also now available. My question is this: is it enough to establish the FAS link by demonstrating a reduction in apoptosis with either of these agents (the anti-FASL antibody or the Fc fragment) or is it necessary to use both? I appreciate any and all comments. Thomas L. Morgan, Ph.D. Department of Radiation Oncology Kaiser Permanente Medical Center 4950 Sunset Blvd. Los Angeles, CA 90027 213-667-3560 213-667-4568
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:49:36 EST